Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993)

Philip J. Bergman, E. Gregory MacEwen, Ilene D. Kurzman, Carolyn J. Henry, Alan S. Hammer, Deborah W. Knapp, Ann Hale, Stephen A. Kruth, Mary K. Klein, Jeffrey Klausner, Alan M. Norris, Dudley McCaw, Rodney C. Straw, Stephen J. Withrow

Research output: Contribution to journalReview articlepeer-review

184 Scopus citations


Forty-eight dogs with histologically confirmed appendicular osteosarcoma (OSA) entered a prospective clinical trial evaluating treatment with amputation and up to 4 doses of carboplatin given every 21 days. The median disease-free interval (DFI) was 257 days, with 31.2% of the dogs disease-free at 1 year. The median survival time was 321 days, with 35.4% of the dogs alive at 1 year. Dogs with proximal humeral OSA had shorter DFI (P = .016) and survival (P = .037) times than dogs with OSA at other locations. Dogs with lower body weights (<40 kg) had longer DFI (P = .0056) and survival (P = .007) times than larger dogs. Survival times for dogs that received carboplatin were statistically longer than those previously reported for amputation alone (P < .001). DFI and survival times are similar to those previously reported for 2 to 4 doses of cisplatin. Carboplatin appears to be a well-tolerated chemotherapeutic drug that can be given safely every 21 days at a dose of 300 mg/m2. Neutropenia was the dose-limiting toxicity in this study.

Original languageEnglish (US)
Pages (from-to)76-81
Number of pages6
JournalJournal of veterinary internal medicine
Issue number2
StatePublished - 1996


Dive into the research topics of 'Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993)'. Together they form a unique fingerprint.

Cite this